Insights from the charity sector – from patient engagement to people-driven design
Marianne Guldbrandsen, Strategy Director at Cuttsy+Cuttsy and former Head of Innovation and Strategic Partnerships at Macmillan, discusses how people-driven research leads to truly patient-centred products and services, and what the pharmaceutical industry can learn about this from the charity sector.
The charity sector has a reputation for being good at bringing their key stakeholder to the core of everything they do. With the term ‘patient-centric’ being heard more and more in the pharma industry, there are things we can learn from the charity sector about the breadth and depth of how to involve and support patients and their families.
When
talking about being patient-centric, the devil is in the detail. We can all
agree that engaging patients is important — after all it is their health, care
and treatment we are trying to continuously improve. But if engagement is
merely a matter of involving them in clinical trials, advisory boards, focus
groups or online forums, then we are missing out on great potential for even
better insight, innovation and impact.
Being
truly patient-centric means being people-driven, a subtle but important
difference where we put effort into understanding not just the part of the
person that can be described as a patient, but all of them. It is in
understanding that people are more than patients that we can really make a
difference. They have lives to live, daily activities, work, family, commuting
etc. It means that we don’t just bring them into our processes, but we spend
time to understand the context in which medicines and treatments are
experienced over time. We involve them not just by gaining insights in the
early stages, but in letting them participate throughout the development process.
Depending on what we are creating it might even be appropriate let them
participate in a way that could be described as co-creation. Co-creation means gaining
insights and bringing ideas to fruition through prototyping with the end-user
involved throughout the process.
As an example of how a people-driven approach is being used
in the charity sector, Macmillan Cancer Support created a service for younger
people affected by cancer using deep customer insights, co-design and iterative
prototyping. The starting point was doing customer insight work by spending a
few hours with 20 people in their 20–40s that had recently been through cancer
treatment. This was done in their home or with a researcher following them on
their daily activities, so it was not just a normal interview, but an attempt
to understand their lives in more detail than they could describe themselves in
words. This gave great insight into what was important to these people and what
their needs were after cancer. In analysing the vast amount of data, one
finding was that they were struggling with their ‘new normal’, i.e. what a
normal life feels like with the side effects of their disease or treatment.
After a series of co-creational workshops to come up with ideas, people
affected by cancer were also deeply involved throughout prototyping and testing
of ‘pick me up’ offerings. In the early stages 20–30 people from the target
audience were involved, but as the ideas evolved and the solution got more and
more defined, 300 people took part in early testing of the service. It also
meant continuous evaluation, i.e. was the solution having the impact it set out
to have.
It
is not only in the development of new services that Macmillan involve people
affected by cancer, but across a spectrum of advisory boards, developing policy
position, information resources and local services. It is in the knowledge of when and how to engage with our end customers that we can evolve the field
of patient-centricity and people-driven solutions. From patients as experts to
deep user insights, focus groups and early testing groups, a range of methods
can help us and the people we serve.
There
is no reason why pharma cannot do the same. Patients can be engaged in
compliant and appropriate ways, and the benefits of listening to what they have
to tell us are vast. This is how products and services will be created that
better serve their needs. It is time for pharma to work with patients, and not
just for them. Marianne Guldbrandsen is
Strategy Director at Cuttsy+Cuttsy, a healthcare strategy and comms agency,
where people matter. Previously she spent five years building and heading up
Macmillan Cancer Support’s Innovation & Strategic Partnership team. Coming
from a design background, she set up a multidisciplinary team that has embedded
design thinking across the organisation.
Cuttsy+Cuttsy's charitable programme — Cuttsy Cares — has been running for the past 2 years, providing the team with the opportunity to support causes close to their hearts. Cuttsy + Cuttsy
A catch up with Louise Jones, Cuttsy+Cuttsy's sustainability officer, on what was achieved in 2022, the agency's latest environmental assessment with CDP and a look ahead to 2023. Cuttsy + Cuttsy
Our 2022 Christmas campaign saw Santa’s agency elves creating tailored materials for patients. But were the examples guided by the principles of health literacy? Were they naughty or nice? Cuttsy + Cuttsy